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Abstract
Purpose Peptide receptor radionuclide therapy (PRRT) has
become an important treatment option in the management of
advanced neuroendocrine tumours. Long-lasting responses
are reported for a majority of treated patients, with good tol-
erability and a favourable impact on quality of life. The treat-
ment is usually limited by the cumulative absorbed dose to the
kidneys, where the radiopharmaceutical is reabsorbed and
retained, or by evident haematological toxicity. The aim of
this study was to evaluate how renal function affects (1)
absorbed dose to the kidneys, and (2) the development of
haematological toxicity during PRRT treatment.
Methods The study included 51 patients with an advanced
neuroendocrine tumour who received 177Lu-DOTATATE
treatment during 2006 – 2011 at Sahlgrenska University Hos-
pital in Gothenburg. An average activity of 7.5 GBq
(3.5 – 8.2 GBq) was given at intervals of 6 – 8 weeks on
one to five occasions. Patient baseline characteristics accord-
ing to renal and bone marrow function, tumour burden and
medical history including prior treatment were recorded. Re-
nal and bone marrow function were then monitored during
treatment. Renal dosimetry was performed according to the
conjugate view method, and the residence time for the radio-
pharmaceutical in the whole body was calculated.
Results A significant correlation between inferior renal func-
tion before treatment and higher received renal absorbed dose
per administered activity was found (p<0.01). Patients with
inferior renal function also experienced a higher grade of hae-
matological toxicity during treatment (p=0.01). The residence
time of 177Lu in the whole body (range 0.89 – 3.0 days) was
correlated with grade of haematological toxicity (p=0.04) but
not with renal absorbed dose (p=0.53).
Conclusion Patients with inferior renal function were exposed
to higher renal absorbed dose per administered activity and
developed a higher grade of haematological toxicity during
177Lu-DOTATATE treatment. The study confirms the tolera-
bility of PRRT in patients with an advanced neuroendocrine
tumour but indicates that patients with inferior renal function
are at risk of being exposed to higher absorbed doses to nor-
mal tissue on treatment.
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Introduction
Peptide receptor radionuclide therapy (PRRT) using somato-
statin analogues has now been a valuable treatment option for
advanced neuroendocrine tumours for more than 10 years.
Kwekkeboom et al. in Rotterdam were the first to report the
effectiveness and safety of this treatment [1] and the same
group reported a positive impact on quality of life [2]. PRRT
is well tolerated in general but normal tissue is exposed to
radiation to different degrees. The dose-limiting organ is usu-
ally the kidney, because of active reabsorption of the
radionuclide-labelled somatostatin analogue. Renal uptake is
mediated by the endocytic receptor megalin in the proximal
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tubuli [3]. The amount of PRRT given has often been restrict-
ed by an absorbed dose limit of 23 Gy to the kidneys on the
basis of earlier established knowledge about renal absorbed
dose tolerance from external beam radiation [4].
Efforts have been made to find tolerance doses for the
kidneys that better match the risks from radionuclide therapy
with its different dose rates, dose distributions and fraction-
ation characteristics compared to external beam radiation
[5–7]. Bodei et al. calculated the biological effective dose
(BED) using a linear quadratic model adapted to radionuclide
therapy. They showed that a safe renal absorbed dose limit for
PRRT (90Y-DOTATOC and 177Lu-DOTATATE) might be a
BED of around 40 Gy in patients without risk factors for renal
toxicity and 28 Gy in patients with certain risk factors, includ-
ing hypertension, diabetes mellitus and other conditions
known to affect renal function [8]. Also Gupta et al. recently
demonstrated the relevance of using different absorbed dose
limits to the kidneys based on renal function. In their study,
PRRT showed a greater effect on renal function in patients
with inferior glomerular filtration rate (GFR) initially than in
patients with superior renal function [9].
In clinical practice haematological toxicity sometimes
becomes relevant; a toxicity of grade 3 or 4 according to
the Common Terminology Criteria for Adverse Events
(CTCAE) of the US National Cancer Institute has been
reported in approximately 10% of patients after one or
more PRRT treatments of [9–12]. Possible risk factors for
haematological toxicity include previous chemotherapy,
low creatinine clearance and bone metastases [13]. Other
toxicities such as liver toxicity might occur during PRRT
but much less frequently [10]. The normal tissue reported
to receive the highest absorbed dose is the spleen [14, 15].
However, compromised spleen function has not been re-
ported after PRRT.
It has been reported that transient deterioration of renal
function can have an important effect on the absorbed dose
to normal tissue from PRRT [16]. The aim of this study was to
analyse what impact renal function has on renal absorbed dose
and the development of haematological toxicity. Factors
known to affect renal and bone marrow function including
hypertension, diabetes, older age, previous chemotherapy
and comedication were noted [8, 17]. Because tumour burden
and whole-body content kinetics for the radiopharmaceutical
could affect the radiation exposure of kidneys and bone mar-
row, these factors were also analysed.
Materials and methods
Patients and treatment characteristics
This retrospective study was approved by the Regional
Ethics Review Board in Gothenburg and performed in
accordance with the principles of the Declaration of
Helsinki and national regulations. The need for written
informed consent was waived. From March 2006 to De-
cember 2011, 51 patients with an advanced neuroendo-
crine tumour were treated with 177Lu-DOTATATE at
Sahlgrenska University Hospital in Gothenburg
(Table 1). Patients considered for treatment had progres-
sive disease detected by radiology, enhanced carcinoid
symptoms or increasing tumour markers. All patients
had a WHO performance status of 0 – 2 and a tumour
uptake on somatostatin receptor scintigraphy (111In-
DTPA0 octreotide, Octreoscan®; Mallinckrodt) judged
to exceed normal liver uptake. Patients with moderately
reduced renal function were accepted, that is those with
a GFR of 40 ml/min (i.e. chronic kidney disease stage 3
[18]) or more, based on 51Cr-EDTA clearance. An av-
erage amount of 7.5 GBq (3.5 – 8.2 GBq) 177Lu-
DOTATATE was given as a 30-min intravenous infusion
coadministered with kidney-protective amino acids
(2.5 % lysine and 2.5 % arginine in 1 L of 0.9 % NaCl;
rate of infusion 250 mL/h) on three (one to five) occa-
sions 8 weeks (6 – 10 weeks) apart. The number of
treatments was usually limited by the absorbed dose to
the kidneys, but in some patients the number of treat-
ments was limited by disease progression (three pa-
tients) or persistent haematological toxicity (four
patients).Subgroups (26 and 33) of these patients had
previously been studied concerning safety, efficacy and
variations in renal dosimetry [19, 20].
Table 1 Patient characteristics















Hepatic artery embolization 16
Chemotherapy 15
External beam radiation 3
Liver transplantation 4
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Dosimetry
For all analyses in this study, the absorbed dose to the kidneys
and the whole-body residence time for 177Lu for the first treat-
ment cycle were used. The conjugate view method [21] was
applied to planar images obtained 1.5, 24, 48 and 168 h after
injection. The gamma cameras used were a Picker IRIX (Mar-
coni, Philips, The Netherlands) and a Millennium VG Hawk-
eye (General Electric Medical Systems, Milwaukee, WI),
equipped with medium-energy parallel-hole collimators. The
CT images were generated by the Millennium VG Hawkeye
system.
The effective attenuation coefficient and sensitivity for the
gamma cameras were determined by planar scintigraphy of a
planar 177Lu source equal to the cross-sectional area of a stan-
dard kidney placed at different depths in a phantom of tissue
equivalent material. The counts in a region of interest (ROI)
drawn around the 177Lu source were recorded from the planar
images. A monoexponential curve was fitted to the number of
counts versus depth data, and the effective attenuation coeffi-
cient and sensitivity were determined. The thickness of the
body over the kidney and the kidney thickness were deter-
mined from a low-resolution CT scan performed 24 h after
injection. The counts in the anterior and posterior images in
a ROI around the kidney were recorded and the counts in a
background ROI located caudal to the kidney ROI were
subtracted. The background counts were adjusted to account
for the overlying and underlying tissue in the kidney ROI. In
patients in whom it was not possible to separate the liver
uptake from the right kidney uptake, or to separate tumour
uptake from the uptake in one of the kidneys, the activity in
that kidney was calculated from only a part of the kidney
(right kidney in 33 patients, left kidney in 33 patients). If the
kidney could not be delineated at all (5 patients), the activity
concentration was determined in a SPECT image 24 h after
injection and the kinetics from the left kidney were used.
To calculate the absorbed dose to the kidneys, the effective
attenuation coefficient, sensitivity, anterior and posterior
counts, and patient and kidney thickness were inserted into
the conjugate view formula. This procedure is described else-
where [20]. The activity obtained was divided by the kidney
mass, which was estimated assuming an ellipsoid, and the
lengths of the three axes were determined from high-
resolution CT images obtained before treatment. A
monoexponential curve fit was applied to the time–activity
data and the accumulated specific activity calculated. The
absorbed dose was estimated by assuming local absorption
of the charged particles emitted from 177Lu (mean energy
per decay equal to 147 keV [22]).
To evaluate other factors possibly affecting radiation expo-
sure of normal tissue, the variation in residence time of the
radiopharmaceutical in the whole body was analysed. The
whole-body content was determined by the conjugate view
method, and in the 24 patients who had not urinated this re-
sulted in a calculated whole-body activity from the planar
image obtained 1.5 h after injection that was 94±8.5 % of
the injected activity using the patient thickness over the kid-
neys. There was a trend towards an increase in estimated ac-
tivity with increasing patient thickness (1.1 %/cm). The pa-
tient thickness in the study was between 16 and 28 cmmaking
a maximal deviation of 13 %. The patient thickness in the
conjugate view formula was therefore calibrated to make the
measured activity at 1.5 h after injection equal to the injected
activity of the patients who had not urinated, resulting in a
relative standard deviation of 8 % with no patient thickness
dependence. This method for calibrating patient thickness was
applied in all 51 patients to determine the whole-body resi-
dence time.
Bone marrow dosimetry was not performed in this study
because previous studies had shown that the absorbed dose to
the bone marrow is usually low [15, 23]. This has recently
been confirmed by a study of bone marrow dosimetry during
177Lu-DOTATATE therapy indicating that the absorbed dose
to the bone marrow is less than 0.2 Gy per treatment cycle of
7.4 GBq [24].
Tumour burden
Patient tumour burden was visually estimated in the planar
images obtained 24 h after injection from the first treatment
and graded from 1 (minor tumour burden) to 5 (major tumour
burden; Fig. 1). For comparative analysis patients graded 1 or
2 were considered to have a small tumour burden, patients
graded 3 were considered to have a medium tumour burden
and patients graded 4 or 5 were considered to have a large
tumour burden.
Renal and haematological toxicity
The patients were monitored clinically and according to renal
and haematological toxicity during the treatment period by
regular measurements of serum creatinine and haemoglobin,
leucocytes and platelets. Toxicity was graded from 0 to 5
according to the CTCAE 4.0 of the NCI.
Statistical analysis
To report normally distributed continuous variables, means
and standard deviation are used. Possible relationships be-
tween variables were evaluated by independent-sample t tests
and linear regression. For all statistical analyses the statistical
software IBM SPSS 19 was used and p values less than 0.05
were considered significant.
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Results
Patients with inferior renal function, estimated by GFR before
treatment, were exposed to significantly higher renal absorbed
doses (p<0.01, Fig. 2) during their first 177Lu-DOTATATE
treatment.. The data showed considerable variation and more
markedly so in patients within the lower range of GFR. Pa-
tients with GFR ≤60 ml/min (i.e. chronic kidney disease stage
1 [18]; 10 patients) received renal absorbed doses of 0.83±
0.35 Gy/GBq and patients with GFR ≥90 ml/min (11 patients)
Fig. 1 Examples of patients
classified as having a small (a
grade 1), medium (b grade 3) and
large (c grade 5) tumour burden.
The patient with a small tumour
burden (a) has a single tumour
located in the abdomen, the
patient with a medium tumour
burden (b) has multiple tumours
in the abdomen, and the patient
with a large tumour burden (c) has
multiple tumours in the liver
involving around 50 % of the
parenchyma
Fig. 2 Patients with inferior renal
function estimated by GFR (from
51Cr-EDTA clearance) received
higher renal absorbed doses per
injected amount of 177Lu-
DOTATATE
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received renal absorbed doses of 0.49±0.09 Gy/GBq
(p<0.01). The other patients (GFR >60 to <90 ml/min) re-
ceived renal absorbed doses of 0.64±0.16 Gy/GBq.
Conditions known to affect renal function, including age,
comorbidity (hypertension or diabetes mellitus), prior chemo-
therapy and comedication, were explored to determine if there
were differences in received absorbed dose to the kidneys.
Renal function declines physiologically with age, and a trend
toward this was seen among patients in this study, but the
differences were not statistically significant. Baseline GFR
was 65±16 ml/min in patients older than 70 years (8 patients)
and 77±16 ml/min in younger patients (43 patients, p=0.07),
and consequently patients older than 70 years at the time of
treatment were not exposed to significantly higher renal
absorbed doses (0.76±0.31 Gy/GBq compared with 0.62±
0.20 Gy/GBq for the younger group, p=0.12). Patients with
hypertension (15 patients) and patients previously exposed to
chemotherapy (15 patients) did not differ in their renal func-
tion as estimated by GFR compared with the other patients.
GFR was 76±16 ml/min in patients without hypertension and
73±17 ml/min in patients with hypertension (p=0.56), and
baseline GFR was 73±16 ml/min in patients not exposed to
chemotherapy and 79±17 ml/min in those who had been ex-
posed to chemotherapy (p=0.26). Renal absorbed doses were
similar in these groups. Renal absorbed dose/injected activity
was 0.63±0.20 Gy/GBq in patients without hypertension and
0.69±0.28 Gy/GBq in patients with hypertension (p=0.39).
Renal absorbed dose was 0.68±0.23 Gy/GBq in patients not
exposed to chemotherapy and 0.57±0.21 Gy/GBq in those
who had been exposed to chemotherapy (p=0.12). Patients
with diabetes mellitus (two patients) and patients on
medication with a potential effect on renal function, such as
nonsteroidal antiinflammatory drugs (two patients), were too
few to analyse. All patients were monitored according to their
renal function during the treatment period, with no signs of
renal toxicity detected, as estimated using serum creatinine.
Renal function was also correlated with the development of
haematological toxicity during treatment. GFR was 89±9 ml/
min in patients who did not experience haematological toxic-
ity (grade 0 according to CTCAE) and 56±6 ml/min in those
developing the highest toxicity (grade 3). Although the groups
were small (three patients with CTCAE grade 0, four patients
with grade 3), the mean values differed significantly (p<0.01,
Fig. 3). Patients with bone metastases could be at higher risk
of developing haematological toxicity. In this study 11 of 18
patients (61 %) with bone metastases developed grade 2 or 3
haematological toxicity compared with 13 of 30 (43 %) of the
other patients. Previous exposure to chemotherapy may also
affect bone marrow function, but it was not associated with a
higher frequency of haematological toxicity in this study. Of
34 patients not exposed to chemotherapy, 16 (47 %) experi-
enced grade 2 or 3 haematological toxicity, compared with 7
of 14 patients previously exposed to chemotherapy (50 %).
No patients developed grade 4 or 5 haematological toxicity.
To evaluate other factors possibly affecting radiation expo-
sure of normal tissue during PRRT treatment, variations in
residence time for the radiopharmaceutical in the whole body
as well as tumour burden were analysed. There was no corre-
lation between renal function and the whole-body residence
time of 177Lu, and the residence time did not affect renal
absorbed dose. However, patients with a longer whole-body
residence time of 177Lu tended to develop a higher grade of
Fig. 3 Patients with inferior renal
function tended to develop a
higher grade of haematological
toxicity during 177Lu-DOTATA
TE treatment according to
CTCAE
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haematological toxicity. Residence time was 2.3±0.5 days in
patients who developed grade 3 haematological toxicity and
1.4±0.1 days in patients who did not experience haematolog-
ical toxicity (p=0.04, Fig. 4a).
To evaluate the relationship between tumour burden and
radiation exposure of normal tissue, tumour burden was visu-
ally estimated as small (grade 1 and 2), medium (grade 3) or
large (grade 4 and 5) in planar images obtained 24 h after
treatment. Residence time was 2.0±0.7 days in patients with
a large tumour burden and 1.3±0.2 days in patients with a
small tumour burden (p<0.01, Fig. 4b). GFR was 72±
14 ml/min in 23 patients with a large tumour burden and 84
±11 ml/min in 11 patients with a small tumour burden (p=
0.02). Despite differences in renal function, renal absorbed
dose per injected activity of 177Lu-DOTATATE did not differ
between patients with a large and a small tumour burden: 0.63
±0.20 Gy/GBq vs. 0.62±0.11 Gy/GBq (p=0.88). However,
the frequency of haematological toxicity seemed higher
Fig. 4 Longer whole-body
residence time of 177Lu was
associated with a higher grade of
haematological toxicity (a) and a
larger tumour burden (b)
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among patients with a large tumour burden: among patients in
whom haematological toxicity could be evaluated, 12 of 21
(57 %) with a large tumour burden and 4 of 11 (36 %) with a
small tumour burden experienced grade 2/3 haematological
toxicity.
Discussion
Patients with inferior renal function as estimated by GFRwere
exposed to significantly higher renal absorbed dose during
their first 177Lu-DOTATATE treatment in this study. The var-
iation was considerable, and appeared to be higher among
patients with inferior renal function. This variation is probably
due to both physical and biological issues. Physical variations
are known to be larger in the two-dimensional conjugate view
method used, compared to three-dimensional dosimetry [20,
25]. A correlation was found between GFR and the two-
dimensional estimated renal absorbed dose in this study, but
a patient-specific prediction of the renal absorbed dose from
the GFR was not possible due to the substantial variation.
Future studies with three-dimensional renal dosimetry could
improve the precision and enable a patient-specific use of the
correlation found. A disadvantage of three-dimensional do-
simetry is that only a limited part of the body is usually stud-
ied, which is insufficient for whole-body dosimetry. Neverthe-
less, the physical variations would be expected to remain con-
stant independent of renal function. Therefore, the observed
increased variation seen along with decreasing renal function
may be due to biological phenomena. One reason for this
could be heterogeneity in the kind of renal impairment present
among the patients. Themethod chosen to estimate renal func-
tion in this study, GFR, is a measure of glomerular function
and does not measure tubular function. Patients with lower
GFR might differ in tubular function more markedly, which
could affect tubular reabsorption ability and exposure to the
radiopharmaceutical from the primary urine. Tubular function
was not estimated in this study, for example by measuring the
ratio of protein HC (α1-microglobulin) to creatinine in urine
[26] or by performing a 99mTc-MAG3 renal scan [27].
Other factors known to affect the kidneys are hypertension
and previous chemotherapy. Guerriero et al. [28] found a sig-
nificant difference in renal absorbed dose between patients
with hypertension and previous chemotherapy and other pa-
tients. In our study neither hypertension nor previous chemo-
therapy seemed to affect the absorbed dose to the kidneys. The
reason for these different findings could be that patients in our
study had better renal function at the time of treatment. Pa-
tients with newly diagnosed, well-regulated hypertension of-
ten have normal renal function while patients with
longstanding, insufficiently regulated hypertension may have
developed clinically significant renal dysfunction [29]. Pa-
tients with previous chemotherapy are also a heterogeneous
group inwhom treatment dosages vary, as do agents. Of the 15
patients in this study who had received chemotherapy, the
therapy given to 13 was known to potentially affect the kid-
neys (streptozotocin or cisplatin) [30], but the GFR did not
differ between these patients and the other patients at the time
of PRRT. The time between completed chemotherapy and the
start of PRRT, a median of 9 months in this study, will prob-
ably also affect the condition of the kidneys.
In addition to being exposed to higher renal absorbed
doses, patients with inferior renal function also tended to ex-
perience a higher grade of haematological toxicity according
to CTCAE. Another factor that can potentially affect the bone
marrow and the consequent development of haematological
toxicity is the presence of bone metastases. These patients did
experience a higher frequency of moderate haematological
toxicity (grade 2/3) in this study, as previously shown by
Kam et al. [13]. However, no correlation was seen between
previous exposure to chemotherapy and haematological tox-
icity, in contrast to the findings of Kam et al. [13]. As men-
tioned above, this may be because of heterogeneity in the
chemotherapy group. It should also be taken into account that
the subgroups that were compared, developing grade 0 and
grade 3 haematological toxicity, respectively, were small.
To evaluate other differences in radiation exposure of nor-
mal tissue, the residence time of 177Lu in the whole body as
well as patient tumour burden were analysed. It might have
been expected that the whole-body residence time would in-
crease with a lower GFR, but this was not seen in the present
study. We are aware of the uncertainties in the method used,
but the lack of correlation still indicates that factors other than
renal function probably contribute to the residence time. One
factor affecting the residence time of 177Lu in this study was
tumour burden. Interestingly, a longer residence time was as-
sociated with an increase in haematological toxicity but not
renal absorbed dose. One reason for this may be that a higher
tumour burden increases the radiation exposure of the bone
marrow whereas the kidneys may instead be protected from
irradiation because a higher proportion of the radiopharma-
ceutical accumulates in the tumour. Garske et al. found that
decreasing tumour burden during multiple 177Lu-DOTATATE
treatments was associated with a higher renal absorbed dose
but a lower estimated bone marrow absorbed dose [31, 32].
The estimated renal absorbed dose did not differ between pa-
tients with a large and a small tumour burden in this study. A
reason for this could have been that patients with a smaller
tumour burden had a better estimated renal function before
treatment, which could have compensated for the expected
tendency to receive a relatively higher renal absorbed dose,
as noted by Garske et al. [31].
More detailed bone marrow dosimetry studies [33, 34]
have shown no evident correlation between received bone
marrow absorbed dose and the development of haematologi-
cal toxicity. This indicates that other factors affect
Eur J Nucl Med Mol Imaging (2015) 42:947–955 953
haematological toxicity. Sabet et al. found that during the
long-term follow-up of PRRT patients, a history of splenecto-
my (in 16 patients) was inversely associated with the inci-
dence of haematological toxicity [11]. The spleen, where
blood cells are pooled, is known to be exposed to the highest
absorbed doses during PRRT [14]. However, a possible cor-
relation between the absorbed dose to the spleen and haema-
tological toxicity remains to be studied.
Acknowledgments The authors greatly appreciate and acknowledge
Rebecca Hermann for her technical assistance. This work was supported
financially by the Swedish Cancer Society, Swedish Radiation Safety
Authority, the King Gustav V Jubilee Clinic Cancer Research Foundation
and the Swedish Research Council.
Conflicts of interest None.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
1. Kwekkeboom DJ, de Herder WW, van Eijck CH, Kam BL, van
Essen M, Teunissen JJ, et al. Peptide receptor radionuclide therapy
in patients with gastroenteropancreatic neuroendocrine tumors.
Semin Nucl Med. 2010;40:78–88.
2. Khan S, Krenning EP, van Essen M, Kam BL, Teunissen JJ,
Kwekkeboom DJ. Quality of life in 265 patients with
gastroenteropancreatic or bronchial neuroendocrine tumors treated
with [177Lu-DOTA0,Tyr3] octreotate. J NuclMed. 2011;52:1361–8.
3. Melis M, Krenning EP, Bernard BF, Barone R, Visser TJ, de Jong M.
Localisation and mechanism of renal retention of radiolabelled so-
matostatin analogues. Eur J Nucl Med Mol Imaging. 2005;32:1136–
43.
4. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE,
et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat
Oncol Biol Phys. 1991;21:109–22.
5. Dale R, Carabe-Fernandez A. The radiobiology of conventional ra-
diotherapy and its application to radionuclide therapy. Cancer Biother
Radiopharm. 2005;20:47–51.
6. Dale R. Use of the linear-quadratic radiobiological model for quan-
tifying kidney response in targeted radiotherapy. Cancer Biother
Radiopharm. 2004;19:363–70.
7. Strigari L, Benassi M, Chiesa C, Cremonesi M, Bodei L, D′Andrea
M. Dosimetry in nuclear medicine therapy: radiobiology application
and results. Nucl Med Mol Imaging. 2011;55:205–21.
8. Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM,
Bartolomei M, et al. Long-term evaluation of renal toxicity after
peptide receptor radionuclide therapy with 90Y-DOTATOC and
177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl
Med Mol Imaging. 2008;35:1847–56.
9. Gupta SK, Singla S, Bal C. Renal and hematological toxicity in
patients of neuroendocrine tumors after peptide receptor radionuclide
therapy with 177Lu-DOTATATE. Cancer Biother Radiopharm.
2012;27:593–9.
10. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van
Essen M, Kooij PP, et al. Treatment with the radiolabeled somato-
statin analog [177Lu-DOTA 0,Tyr3] octreotate: toxicity, efficacy, and
survival. J Clin Oncol. 2008;26:2124–30.
11. Sabet A, Ezziddin K, Pape UF, Ahmadzadehfar H, Mayer K, Poppel
T, et al. Long-term hematotoxicity after peptide receptor radionuclide
therapy with 177Lu-octreotate. J Nucl Med. 2013;54:1857–61.
12. Garkavij M, Nickel M, Sjogreen-Gleisner K, Ljungberg M, Ohlsson
T, Wingardh K, et al. 177Lu-[DOTA0,Tyr3] octreotate therapy in
patients with disseminated neuroendocrine tumors: analysis of do-
simetry with impact on future therapeutic strategy. Cancer.
2010;116:1084–92.
13. Kam BL, Teunissen JJ, Krenning EP, de Herder WW, Khan S, van
Vliet EI, et al. Lutetium-labelled peptides for therapy of neuroendo-
crine tumours. Eur J NuclMedMol Imaging. 2012;39 Suppl 1:S103–
12.
14. Bodei L, CremonesiM, Grana CM, Fazio N, Iodice S, Baio SM, et al.
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the
IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38:2125–
35.
15. Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW,
Srinivasan A, Erion JL, et al. [177Lu-DOTAOTyr3] octreotate: com-
parison with [111In-DTPAo] octreotide in patients. Eur J Nucl Med.
2001;28:1319–25.
16. Van Binnebeek S, Baete K, Terwinghe C, Vanbilloen B, Haustermans
K, Mortelmans L, et al. Significant impact of transient deterioration
of renal function on dosimetry in PRRT. AnnNuclMed. 2013;27:74–
7.
17. Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de
Jong M, et al. Long-term follow-up of renal function after peptide
receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide
and (177)Lu-DOTA(0),Tyr(3)-octreotate. J Nucl Med. 2005;46
Suppl 1:83S–91.
18. Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012;379:165–
80.
19. Sward C, Bernhardt P, Ahlman H,Wangberg B, Forssell-Aronsson E,
Larsson M, et al. [177Lu-DOTA0-Tyr3]-octreotate treatment in pa-
tients with disseminated gastroenteropancreatic neuroendocrine tu-
mors: the value of measuring absorbed dose to the kidney. World J
Surg. 2010;34:1368–72.
20. Larsson M, Bernhardt P, Svensson JB, Wangberg B, Ahlman H,
Forssell-Aronsson E. Estimation of absorbed dose to the kidneys in
patients after treatment with 177Lu-octreotate: comparison between
methods based on planar scintigraphy. EJNMMI Res. 2012;2:49.
21. Fleming JS. A technique for the absolute measurement of activity
using a gamma camera and computer. Phys Med Biol. 1979;24:
176–80.
22. Eckerman K, Endo A. ICRP Publication 107. Nuclear decay data for
dosimetric calculations. Ann ICRP. 2008;38:7–96.
23. Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in
peptide radionuclide receptor therapy: a review. J Nucl Med.
2006;47:1467–75.
24. Sandstrom M, Garske-Roman U, Granberg D, Johansson S,
Widstrom C, Eriksson B, et al. Individualized dosimetry of kidney
and bone marrow in patients undergoing 177Lu-DOTA-octreotate
treatment. J Nucl Med. 2013;54:33–41.
25. He B, Du Y, Segars WP, Wahl RL, Sgouros G, Jacene H, et al.
Evaluation of quantitative imaging methods for organ activity and
residence time estimation using a population of phantoms having
realistic variations in anatomy and uptake. Med Phys. 2009;36:
612–9.
26. Grubb A, Christensson A. Time for new measurements in kidney
disease diagnosis and follow-up. Lakartidningen. 2013;110:1021–4.
27. Durand E, Chaumet-Riffaud P, Grenier N. Functional renal imaging:
new trends in radiology and nuclear medicine. Semin Nucl Med.
2011;41:61–72.
28. Guerriero F, Ferrari ME, Botta F, Fioroni F, Grassi E, Versari A, et al.
Kidney dosimetry in 177Lu and 90Y peptide receptor radionuclide
therapy: influence of image timing, time-activity integration method,
and risk factors. Biomed Res Int. 2013;2013:935351.
954 Eur J Nucl Med Mol Imaging (2015) 42:947–955
29. Montecucco F, Pende A, Quercioli A, Mach F. Inflammation in the
pathophysiology of essential hypertension. J Nephrol. 2011;24:23–
34.
30. Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG. Phase II/III
study of doxorubicin with fluorouracil compared with streptozocin
with fluorouracil or dacarbazine in the treatment of advanced carci-
noid tumors: Eastern Cooperative Oncology Group Study E1281. J
Clin Oncol. 2005;23:4897–904.
31. Garske U, Sandstrom M, Johansson S, Granberg D, Lundqvist H,
Lubberink M, et al. Lessons on tumour response: imaging during
therapy with (177)Lu-DOTA-octreotate. A case report on a patient
with a large volume of poorly differentiated neuroendocrine carcino-
ma. Theranostics. 2012;2:459–71.
32. Garske U, Sandstrom M, Johansson S, Sundin A, Granberg D,
Eriksson B, et al. Minor changes in effective half-life during fraction-
ated 177Lu-octreotate therapy. Acta Oncol. 2012;51:86–96.
33. Forrer F, Krenning EP, Kooij PP, Bernard BF, Konijnenberg M,
Bakker WH, et al. Bone marrow dosimetry in peptide receptor radio-
nuclide therapy with [177Lu-DOTA(0),Tyr(3)] octreotate. Eur J Nucl
Med Mol Imaging. 2009;36:1138–46.
34. Sandstrom M, Garske U, Granberg D, Sundin A, Lundqvist H.
Individualized dosimetry in patients undergoing therapy with
(177)Lu-DOTA-D-Phe(1)-Tyr(3)-octreotate. Eur J Nucl Med Mol
Imaging. 2010;37:212–25. doi:10.1007/s00259-009-1216-8.
Eur J Nucl Med Mol Imaging (2015) 42:947–955 955
